Changes in BQCA Allosteric Modulation of [H-3]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations
Brian Dean, Shaun Hopper, P Jeffrey Conn, Elizabeth Scarr
NEUROPSYCHOPHARMACOLOGY | NATURE PUBLISHING GROUP | Published : 2016
BD, SH and ES declare no conflict of interest. PJC receives or has received research support in the past 3 years from NINDS, Bristol Myers-Squibb, Johnson and Johnson, AstraZeneca, Michael J Fox Foundation, Thome Foundation, and the Dystonia Foundation. PJC is an inventor on patents that protect different classes of M1 PAMs. He has consulted over the past 3 years for Pfizer and received compensation. Over the past 3 years, he has served on the Scientific Advisory Boards of Seaside Therapeutics, Michael J Fox Foundation, Stanley Center for Psychiatric Research Broad Institute (MIT/Harvard), Karuna Pharmaceuticals, Lieber Institute for Brain Development Johns Hopkins University, Clinical Mechanism (POCM) and Proof of Concept (POC) Consortium, Brain and Behavior Research Foundation, and Neurobiology Foundation for Schizophrenia and Bipolar Disorder.